- Home
- ODD vs OMER Comparison
ODD vs OMER Comparison
Compare ODD & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ODD | OMER |
|---|---|---|
| Founded | 2018 | 1994 |
| Country | Israel | United States |
| Employees | N/A | 202 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 801.3M | 788.4M |
| IPO Year | 2022 | 2008 |
Fundamental Metrics
Financial Performance| Metric | ODD | OMER |
|---|---|---|
| Price | $13.36 | $10.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $44.60 | $32.50 |
| AVG Volume (30 Days) | ★ 3.6M | 713.1K |
| Earning Date | 04-28-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.88 | N/A |
| P/E Ratio | $16.73 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.80 | $2.95 |
| 52 Week High | $79.18 | $17.65 |
Technical Indicators
Market Signals| Indicator | ODD | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 29.80 | 42.16 |
| Support Level | $10.80 | $10.55 |
| Resistance Level | $32.72 | $11.93 |
| Average True Range (ATR) | 0.89 | 0.45 |
| MACD | 0.69 | -0.05 |
| Stochastic Oscillator | 54.26 | 24.24 |
Price Performance
Historical ComparisonAbout ODD ODDITY Tech Ltd.
ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.